{"id":25619,"date":"2021-09-09T12:45:42","date_gmt":"2021-09-09T11:45:42","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&#038;p=25619"},"modified":"2021-09-09T12:45:42","modified_gmt":"2021-09-09T11:45:42","slug":"xavier-montalban-ean-2021-ofatumumab-as-a-treatment-option-for-relapsing-multiple-sclerosis","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/multiple-sclerosis\/conference-hub\/xavier-montalban-ean-2021-ofatumumab-as-a-treatment-option-for-relapsing-multiple-sclerosis\/","title":{"rendered":"Xavier Montalban, EAN 2021: Ofatumumab as a Treatment Option for Relapsing Multiple Sclerosis"},"content":{"rendered":"<p>It was a pleasure to meet with <strong>Prof. Xavier Montalban<\/strong> (Multiple Sclerosis Centre of Catalonia, Vall d\u2019Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis.<\/p>\n<p>The abstract entitled: \u2018Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design\u2019 was presented at the 7th Congress of the European Academy of Neurology &#8211; Virtual 2021.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>Could you tell us a little about ofatumumab and its mechanism of action? (0:15)<\/li>\n<li>What are the advantages of ofatumumab compared to current treatment options for relapsing multiple sclerosis (RMS) in adults with active disease? (0:36)<\/li>\n<li>What have recent clinical trial data taught us about the efficacy and safety of ofatumumab in adults with RMS? (1:15)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Xavier Montalban has received speaking honoraria and\/or travel expenses for participation in scientific meetings, and\/or has been a steering committee member of clinical trials and\/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb\/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch<\/p>\n<p><em><strong>Filmed as a highlight of the EAN Congress, Virtual 2021.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d\u2019Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis. The abstract entitled: \u2018Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design\u2019 [&hellip;]<\/p>\n","protected":false},"featured_media":25617,"template":"","class_list":["post-25619","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-multiple-sclerosis","video_categories-ean-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/25619"}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/25619\/revisions"}],"predecessor-version":[{"id":25620,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/25619\/revisions\/25620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/25617"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=25619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}